Bio-Rad Laboratories (NYSE:BIO.B) Shares Down 17.3%

Bio-Rad Laboratories, Inc. (NYSE:BIO.B) fell 17.3% during trading on Friday . The company traded as low as $279.91 and last traded at $279.91. 400 shares traded hands during mid-day trading, a decline of 66% from the average session volume of 1,193 shares. The stock had previously closed at $338.55.

Bio-Rad Laboratories Price Performance

The company’s 50 day simple moving average is $320.27 and its 200 day simple moving average is $314.95. The stock has a market cap of $7.98 billion, a P/E ratio of -13.03 and a beta of 0.70. The company has a debt-to-equity ratio of 0.14, a current ratio of 5.83 and a quick ratio of 4.34.

Bio-Rad Laboratories (NYSE:BIO.B) last announced its quarterly earnings results on Thursday, February 15th. The company reported $3.10 earnings per share for the quarter. The firm had revenue of $681.18 million for the quarter. Bio-Rad Laboratories had a negative net margin of 23.86% and a positive return on equity of 3.90%.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes.